Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
Lida Kalmanti(Heidelberg University), Frank Stegelmann(University Hospital Ulm), Karsten Spiekermann(German Cancer Research Center), Susanne Saußele(University of Mannheim), Michael Pfreundschuh(Saarland University), Jolanta Dengler(Heidelberg University), Christof Scheid(Centrum für Integrierte Onkologie), Sébastien Rinaldetti(Heidelberg University), Andreas Hochhaus(Jena University Hospital), Benjamin Hanfstein(Heidelberg University), Christiane Falge(Nuremberg Hospital), Andreas Neubauer(RWTH Aachen University), Elisabeth Oppliger Leibundgut(University Hospital of Bern), Markus Pfirrmann(Ludwig-Maximilians-Universität München), Michael Lauseker(Zimmer Biomet (Germany)), Andreas Burchert(Philipps University of Marburg), Stefan W. Krause(Universitätsklinikum Erlangen), Joerg Hasford(Ludwig-Maximilians-Universität München), Ulrike Proetel(Heidelberg University), Christian Dietz(Technische Universität Darmstadt), M. C. Muller(Heidelberg University), Lothar Kanz(University of Freiburg), Linda Heinrich(Heidelberg University), Alice Fabarius(Heidelberg University), R. Hehlmann(Heidelberg University)
Cited by 274
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820